RxDoctor Payments Data

Edward Oleary, MD

Cardiovascular Disease · Omaha, NENPI 1417908914

Payments from drug & device makers

What this record shows

16 manufacturers reported payments, led by Medtronic at 33.4% of the total. Reporting peaked in 2019 at $12,422 and has fallen 67.6% since, to $4,020 in 2025. Among cardiovascular disease clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,372in general payments, 2019–2025

Across 392 payments — averaging $92.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$12K
  • Boston Scientific$6K
  • Edwards Lifesciences$6K
  • Penumbra, Inc.$3K
  • Abiomed$3K
  • Abbott$2K
  • plus $4K from 10 others
$67,734in research payments, 2019–2025

Across 26 payments — averaging $2605.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$38K
  • Abbott$24K
  • Medtronic$6K

What the payments were for

  • Travel & lodging$19,30053%
  • Food & beverage$17,07247%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,372 in reported general payments places this provider in the 90th percentile of 97 cardiovascular disease providers in Nebraska.

See all cardiovascular disease providers in Nebraska

Medicare billing

Part B allowed, 2024
$116,962
Medicare patients
285
Services billed
773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$89,305
EntrestoSacubitril/Valsartan66$78,648
JardianceEmpagliflozin26$34,214
Repatha SureclickEvolocumab26$13,489
Ranolazine ErRanolazine28$3,636
Atorvastatin Calcium139$1,537
Metoprolol Succinate89$1,472
Ezetimibe53$1,190
Rosuvastatin Calcium52$768
ClopidogrelClopidogrel Bisulfate71$758
Isosorbide Mononitrate ErIsosorbide Mononitrate67$635
Carvedilol58$497
Spironolactone55$482
Losartan Potassium48$428
Lisinopril43$387

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →